{
    "id": 21469,
    "fullName": "KDR positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "KDR (VEGFR2) positive indicates the presence of the KDR gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 3791,
        "geneSymbol": "KDR",
        "terms": [
            "KDR",
            "CD309",
            "FLK1",
            "VEGFR",
            "VEGFR2"
        ]
    },
    "variant": "positive",
    "createDate": "04/21/2016",
    "updateDate": "09/13/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1007,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes, displayed efficacy in inhibiting cell and tumor growth in a variety of solid tumor cell lines and mouse tumor models (PMID: 20978347).",
            "molecularProfile": {
                "id": 21996,
                "profileName": "KDR positive"
            },
            "therapy": {
                "id": 984,
                "therapyName": "Anti-VEGFR2 CAR CD8 lymphocytes",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 719,
                    "pubMedId": 20978347,
                    "title": "Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20978347"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12707,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tanibirumab treatment demonstrated manageable toxicity and preliminary efficacy, resulted in increased circulating Kdr (Vegfr2), Vegf and Pigf, and stable disease in 61% (11/18) of patients with refractory solid tumors (PMID: 28391576; NCT01660360).",
            "molecularProfile": {
                "id": 21996,
                "profileName": "KDR positive"
            },
            "therapy": {
                "id": 2515,
                "therapyName": "Tanibirumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10618,
                    "pubMedId": 28391576,
                    "title": "Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28391576"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5899,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932).",
            "molecularProfile": {
                "id": 21996,
                "profileName": "KDR positive"
            },
            "therapy": {
                "id": 3976,
                "therapyName": "TAS-115",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5188,
                    "pubMedId": 24140932,
                    "title": "The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24140932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1314,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494).",
            "molecularProfile": {
                "id": 21996,
                "profileName": "KDR positive"
            },
            "therapy": {
                "id": 984,
                "therapyName": "Anti-VEGFR2 CAR CD8 lymphocytes",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 1027,
                    "pubMedId": 23633494,
                    "title": "Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23633494"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8334,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803).",
            "molecularProfile": {
                "id": 26230,
                "profileName": "KDR pos RET C634W"
            },
            "therapy": {
                "id": 824,
                "therapyName": "Motesanib",
                "synonyms": null
            },
            "indication": {
                "id": 3973,
                "name": "thyroid gland medullary carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 996,
                    "pubMedId": 21422803,
                    "title": "Anti-tumor activity of motesanib in a medullary thyroid cancer model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21422803"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8415,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lenvima (lenvatinib) inhibited interaction between colorectal cancer cells positive for Flt1 (Vegfr1), KDR (VEGFR2), and FLT4 (Vegfr3) and endothelial cells in culture, resulted in inhibition of angiogenesis and delayed tumor growth in cell line xenograft models (PMID: 25425971).",
            "molecularProfile": {
                "id": 26314,
                "profileName": "FLT1 pos FLT4 pos KDR pos"
            },
            "therapy": {
                "id": 792,
                "therapyName": "Lenvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6642,
                    "pubMedId": 25425971,
                    "title": "E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25425971"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21996,
            "profileName": "KDR positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26230,
            "profileName": "KDR pos RET C634W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26314,
            "profileName": "FLT1 pos FLT4 pos KDR pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}